Efforts Needed to Reach Underserved Communities, Advance Pain Medicine Research: Burel Goodin, PhD
The professor of anesthesiology at Washington University in St. Louis discussed the reasons behind his presentation at the 2023 AHS Annual Meeting on engaging underserved populations in pain medicine research. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
"The issue is that one-size-fits-all type of medicine is no longer where it's at. A lot of the stuff that I talked about when engaging underserved populations speaks to historically marginalized groups. A lot of that is steeped in social determinants of health, whether that's issues pertaining to medical mistrust, and some of that's perpetrated, or manifests from issues around being stigmatized and healthcare system, or even discriminated against sometimes."
In the clinical trial realm, diversity and inclusion are concepts that have gained more attention, but ultimately have not shown through. An overwhelming amount of drug development trials have featured patient cohorts that are typically White, with socioeconomic backgrounds that factor little into clinical outcomes. While this may create more homogenous populations to study, it ultimately leaves out those in underserved populations or areas heavily impacted by social determinants of health.
This is an issue across neurology, and specifically, pain-focused clinical trials. At the recently concluded
Following his presentation, Goodin sat down with NeurologyLive® to provide background on the reasons for the talk, and the ways to create more diverse studies. He spoke about the need to update data on therapeutic approaches for pain relief using more inclusive, ethnocentric, patient populations. Furthermore, he discussed why the ideas behind social determinants of health include several other factors outside of race and ethnicity.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025